La Jolla whips up some love for iron overload drug with promising data snapshot

San Diego Biotechnology Network
San Diego Biotechnology Network
La Jolla whips up some love for iron overload drug with promising data snapshot
Loading
/

With revenue trickling in from its first product and an NDA in place for a second, La Jolla Pharmaceutical is ready to shine a bright light on the third candidate coming through its pipeline.

Jeff Vacirca NY Cancer & Blood

An interim analysis of a Phase II study suggests that LJPC-401 could significantly lower the excess iron levels in patients with hereditary hemochromatosis. The drug ? a subcutaneous injection of synthetic human hepcidin ? induced a mean reduction in TSAT from baseline of 42%, versus 6% on placebo (p<0.0001), marking a clear score on the primary endpoint.

It?s a small study with 12 and 14 patients on the drug and placebo cohorts respectively but apparently looked promising enough to send